How long is a mixed peptide good for?

What actually degrades a mixed vial

The shortlist: four forces the documents below describe acting on a solution that used to be a powder: heat, agitation, light, and contamination, with slower chemistry running underneath all of them. The stability review cited here names many more determinants than four and ranks none of them, so read the four as the ones with a document behind them on this page, not as the four that matter most.

Heat: degradation reactions run faster warm, and the physical-stability literature counts temperature among the parameters that govern peptide aggregation (Zapadka, Interface Focus 2017). That relationship is the whole logic behind the fridge.

Agitation: hard shaking drags air through the liquid and builds fresh surfaces where chains unfold and clump; the same review names agitation and interfaces among the drivers. One approved hormone label tells users to swirl its vial gently and never shake it (Omnitrope label, Sandoz).

Light: that same label keeps its mixed vial inside the carton to shield it from light, which is why the refrigerator shelf is not the storage spot the carton is.

Contamination: every pass of a needle through the stopper is an entry event. The water label's counter is aseptic technique on each entry and withdrawal (Hospira label), and the published record has gone looking for what slips past it: 210 samples from 30 vials punctured repeatedly and held refrigerated for 7 days grew nothing, in a study whose authors still asked for replication (Saoji, Indian J Ophthalmol 2018).

The quiet chemistry: even in a cold, dark, still, sterile vial, the review literature describes chemical modification proceeding on its own schedule, which is why looking fine was never a storage window.

What the bacteriostatic water label actually promises

The ingredient: bacteriostatic water for injection is sterile water carrying 0.9% (9 mg/mL) or 1.1% (11 mg/mL) benzyl alcohol, added as a bacteriostatic preservative (Hospira label, via DailyMed).

The design: it ships as a multiple-dose container, built so repeated withdrawals can be made from it, and the preservative's job is keeping the water itself usable across those entries.

The line that matters: the same label says not to store reconstituted drug solutions at all unless the manufacturer of the dissolved compound directs it. The preservative certifies the water across punctures; it certifies nothing about the mix.

Why it cannot: degradation is a property of the dissolved compound, and the label makes no claim about what benzyl alcohol does for it.

How the water itself is kept: controlled room temperature, 20 to 25°C, per the same label. The cold storage rules on this page belong to the compounds, not to that water.

Two questions, two pages, and they are not the same question: this page is about the mixed vial, meaning the drug once water has entered it, and it holds the clocks. How long an opened container of the water may keep being entered, and where the 28-day figure actually comes from, are answered further down this page from the label, the compounding chapter and the expiration-dating regulation.

What the other page owns: what the fluid is made of, what the preservative costs in a newborn, and which channel the article is supplied through, all read off the prescribing information line by line on the bacteriostatic water label page. Nothing on that page sets a window for what gets dissolved into the water, because nothing on those labels does.

Why the vial arrives as a powder in the first place

The formulation logic: liquid dosage forms of therapeutic proteins and peptides often show instability during handling, so manufacturers pull the water out; the review cited here describes solid, freeze-dried forms as frequently required to maintain stability through storage, transport and administration (Angkawinitwong, Ther Deliv 2015).

The measured contrast: in one temperature study of an engineered blood substitute, freeze-drying stretched the 4°C storage time to 1 year, and the dissolved form held for less time than the dry one (Bian, Artif Cells Nanomed Biotechnol 2016). One engineered protein system is not a research peptide, but it measures the direction the formulation literature describes.

What that means for the vial: the clock this page is about starts when water enters, and the dry powder sitting cold was never on it.

What a real storage window looks like

The shape of verified data: one approved lyophilized somatropin vial ships with 1.14mL of bacteriostatic water at 1.5% benzyl alcohol, mixes to 5 mg/mL, and carries a labeled 21 days in the refrigerator at 2 to 8°C after mixing, with anything left over discarded past that point (Omnitrope label, Sandoz).

The same label's liquid form: the cartridge version, never freeze-dried, gets 28 days after first use under the same refrigeration, a reminder that a window belongs to the formulation and not to the molecule alone.

A different compound, a different clock: a reconstituted fibrin sealant kept its tearing strength and sterility for 50 hours in one study (Eberhard, Int J Pharm 2006). Against 21 days, that is roughly a tenth of the time, from the same broad category of product.

A measured window rather than a labeled one: sincalide, a peptide hormone supplied as a lyophilized powder, was reconstituted in sterile water and sampled at set timepoints by validated HPLC. Little to no chemical degradation appeared over 8 days at room temperature, and the same over 8 days refrigerated, against the manufacturer's stated 8-hour post-reconstitution shelf life. The authors asked for microbial testing over that duration before anyone reads the chemistry as clearance (Belanger, J Nucl Med Technol 2020).

Why research vials have nothing like it: each of those figures exists because someone ran studies on that exact formulation. For BPC-157, a 2026 review searching PubMed, Embase and the Cochrane Library to April 2026 reports no pharmaceutical-grade formulation developed or validated, and no formal excipient compatibility studies (Mateescu, Pharmaceutics 2026). Where there is no characterized formulation, there is nothing for a shelf-life study to be run on, and that is the entire reason this page hedges.

The community windows, and what they are

The framing first: everything in this section is community-reported practice, the numbers people actually run, not verified data. None of it traced to a published per-compound study when we went looking.

Where the month habit comes from: the fridge window people quote matches the shape of approved labels like the somatropin one above; whether that is where it came from, we found nothing that records it.

The other half of how long: a vial's life is also a draw count. A mix holding 2.5mL, drawn 0.1mL at a time, covers 25 draws; drawn 0.3mL at a time, the same liquid is gone in 8 full draws. Whichever runs out first, the calendar or the liquid, ends the vial.

What is genuinely unknown

The missing middle: the published solution-state work does not run at the concentration a mixed research vial actually sits at, or under the storage it actually sees. The semaglutide study held buffered solutions at 25, 40 and 60°C for 28 days and at 80°C for 7, which is a preformulation screen for picking a buffer, not a refrigerator window (Malgave, Eur J Pharm Biopharm 2025).

What a purity report is not: a certificate of analysis reports what one batch measured on the day it was tested. A stability study is a different design, the same material measured again at stated timepoints, which is what the sincalide, fibrin sealant and semaglutide papers each ran and what a single-date certificate does not contain.

Why the page reads the way it does: every verified window above belongs to an approved product with its own studies. The community windows mirror that shape onto research vials, and this page declines to dress it up as data.

How long does reconstituted peptide last in the fridge?

No verified figure exists for a research vial in the literature we pulled; the sourced anchors are 21 days refrigerated on one approved hormone label and a community-reported habit of a few weeks, and only the first of those has a study behind it. The somatropin window holds at 2 to 8°C because the manufacturer measured that formulation at that temperature, not because the number transfers to other molecules. Community practice mirrors the shape of that answer. The contamination side has one small study on its side: multiply-punctured vials held refrigerated for 7 days showed no growth across 210 samples drawn from bevacizumab vials under one protocol. One molecule, one protocol, one week: reassuring, not a blanket clearance.

One document does print a default, and it is far shorter than either: for an unpreserved sterile preparation for injection, the European guidance on maximum shelf life after first opening or reconstitution puts in-use storage at normally no longer than 24 hours at 2 to 8°C, unless the reconstitution or dilution took place in controlled and validated aseptic conditions, and it frames that as a microbiological statement rather than a chemical one (CPMP/QWP/159/96 corr). The labeled 21 days is 504 hours, twenty-one times as long, and the two are not answering the same question: one is a window measured on a single product, the other is default wording for a container opened outside a validated process. A vial mixed with preserved water is not the unpreserved row of that document in any case, and the section on who sets the clock reads the rest of it.

Can you freeze a reconstituted peptide?

The sourced evidence leans against it: the approved label we pulled says plainly not to freeze the mixed vial, and freeze-thaw cycles measurably increased aggregation in antibody work, with the effect climbing across cycles (Zhang, Pharm Res 2012). The community nonetheless reports freezing mixed vials for months, and whether any given research peptide tolerates that is a question the literature we pulled does not answer. Where long storage is the goal, the sourced route is lyophilized and cold, not liquid and frozen.

Does bac water make peptides last longer?

It makes the vial re-enterable: the 0.9% benzyl alcohol in bacteriostatic water is a preservative the label certifies for repeated withdrawals from the same container. What that preservative does for a dissolved peptide's own shelf life is a question the label never answers; it certifies the water, not the solute. Preservative-free sterile water is the label's alternative where benzyl alcohol is the concern, neonatal cases on the label.

Who is supposed to set the clock on a mixed vial?

The window has a name: in-use shelf life. The European note for guidance on in-use stability testing states the purpose of that testing as establishing, where applicable, a period of time during which a multidose product can be used whilst retaining quality within an accepted specification once the container is opened (CPMP/QWP/2934/99, in operation September 2001). It is the output of a study, so where the study was never run there is no in-use shelf life to look up.

What that study has to look like: the same document asks for a minimum of two batches, at least pilot scale, with at least one chosen towards the end of its shelf life. The test is designed to simulate the use of the product in practice, with quantities removed by the withdrawal methods normally used and described in the product literature, at intervals comparable to those which occur in practice, sampled under normal environmental conditions of use.

The parameters it names fall in three families, not one: physical ones such as clarity, closure integrity, particulate matter and particle size; chemical ones including the active substance assay, antimicrobial preservative content, degradation product levels and pH; and microbial ones, total viable count and sterility. A single assay figure on a certificate is one entry in the second of those three.

Where the answer is supposed to end up: that guidance states the in-use shelf life should be stated on the label, and that where space allows there should be a space for the user to write the date of opening or the use-by date. It also states the registration dossier should include either the in-use stability data on which the in-use shelf life is based, or a justification why no in-use shelf life is established. Both routes end in a document, which is what a research vial has none of.

The wording that guidance's companion prints for an injection: the note for guidance on maximum shelf life after first opening or reconstitution prints model label text for preparations for infusion or injection. From a microbiological point of view, it reads, the product should be used immediately, and if not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution or dilution has taken place in controlled and validated aseptic conditions (CPMP/QWP/159/96 corr, in operation July 1998).

That sentence is microbiological, and the one beside it is not: the same model text carries a separate chemical and physical in-use stability line that the applicant completes from its own data, stated as x hours or days at y°C. Two questions, two kinds of evidence, printed one above the other, and the 24 hours answers only the first of them.

Who the guidance says carries the rest: its general statement is that because it is difficult to predict all the possible conditions under which the product will be opened, diluted, reconstituted and stored, the user is responsible for maintaining the quality of the product that is administered to the patient. That sentence is printed in the guidance, not inferred from it.

How long does bac water last once the vial is opened?

The approved label sets no clock on it: the Hospira prescribing information prints one storage condition, 20 to 25°C, and no discard interval tied to first entry, and the words refrigerate, refrigerated and refrigeration are absent from the document we read for this page (Hospira label, via DailyMed). The missing number is the label's answer, not a gap to be filled in from elsewhere.

Where the 28-day figure comes from: the official questions and answers to USP General Chapter 797 describe the requirement that multiple-dose containers not be used for more than 28 days unless otherwise specified on the labeling (USP 797 FAQ, question 188). That is a sterile-compounding requirement about a container in a pharmacy, and it is not printed on this product's own prescribing information.

An in-use limit is not an expiry date: the same document separates the two with a case where a multiple-dose vial carrying a 60-day beyond-use date still has to be discarded no later than 28 days after first puncture (question 193). Two clocks, two starting events, and the shorter one ends the container.

A second document reaches the same number from a different direction: the European guidance quoted in the section above prints, for aqueous preserved sterile products, model label text reading that once opened the product may be stored for a maximum of z days at t°C, and it states the applicant should justify those values case by case, with z normally no greater than 28 days. Bacteriostatic water answers to that description, since benzyl alcohol is named on its own label as a bacteriostatic preservative.

What the two 28s have in common is not a measurement: one is a limit on how long a compounder may keep drawing from a multiple-dose container, the other is a ceiling on what an applicant may normally claim on a label without justifying more. Neither document reports testing a vial of this water, so a figure can be right in two places at once and still not be the result of anyone opening one and watching it.

One bacteriostatic water label does print a discard interval: the TM BIOWATER record on DailyMed reads store at 20 to 25°C, protect from light, refrigerate after opening, discard 30 days after first puncture. DailyMed files that product under the marketing category unapproved drug other and prints beside it the notice that the drug has not been found by FDA to be safe and effective and that this labeling has not been approved by FDA.

So the answer depends on which document you are standing in: 30 days from an unapproved label, 28 days from a compounding chapter and the same ceiling in the European guidance, and no interval at all from the approved one. Not one of them is timing what gets dissolved into the water, which is the clock the rest of this page is about.

How long is bacteriostatic water good for?

Unopened, the answer is printed on the vial in front of you: federal drug regulation requires a finished drug product to bear an expiration date determined by appropriate stability testing, and requires that date to be related to any storage conditions stated on the labeling (21 CFR 211.137, paragraphs a and b). There is no industry-wide interval to quote back, because the date belongs to the batch and to whoever manufactured it.

The same section reaches the mixed product too: where a drug product is to be reconstituted at the time of dispensing, its labeling shall bear expiration information for both the reconstituted and unreconstituted drug products (21 CFR 211.137, paragraph c). That obligation attaches to a filed drug product, which is the category the somatropin label above sits in. A vial sold for research carries no approved labeling for the obligation to attach to.

How much slack can sit behind a printed date, measured once at scale: the Shelf Life Extension Program has been administered by FDA for the United States Department of Defense, and a 2006 report summarized extended stability profiles for 122 different drug products across 3,005 lots. 88% of the lots were extended at least 1 year past their original expiration date, for an average extension of 66 months (Lyon, J Pharm Sci 2006).

The same report explains why that is not a general permission: the additional stability period was highly variable, and its authors conclude that because of lot-to-lot variability the stability and quality of extended products can only be assured by periodic testing and systematic evaluation of each lot. Every extension there rests on testing that lot, and the report's own summary is that many drug products can be extended past the expiration date if properly stored. A punctured vial is a different object, and the in-use limit above is a different clock, so the finding says what a printed date can hide and nothing about either of those.

What the compounding chapter says about reusing a mixed vial: asked whether a reconstituted single-dose vial can be kept cold and reused for later preparations, its questions and answers reply that a vial entered or punctured only in ISO Class 5 or cleaner air may be used up to 12 hours after initial entry or puncture, as long as the labeled storage requirements are maintained (USP 797 FAQ, question 195).

That window only exists inside a cleanroom: the 12 hours is granted to a container entered in ISO Class 5 or cleaner air, so quoting the interval without the air-quality condition converts a compounding standard into a kitchen one.

And the same answer routes the mixed vial back to a manufacturer's document: where the product was reconstituted in advance as a single dose for one patient, that document says the reconstituted solution may be stored per the approved labeling. Every route it offers ends at approved labeling, which is exactly what the searches recorded above did not turn up for a research peptide.

What none of it settles: every source above times either a container or a licensed product. A mixed research vial is neither, so the honest answer stays the one at the top of this page.

How can you tell a mixed vial has gone bad?

The reliable sign is the one the labels we pulled print: cloudiness or visible particles ends the vial on sight. The mixed-hormone label carries that inspection rule in so many words, and the water's label carries its own version. What no inspection catches is everything else on the degradation list, and the hormone label sets its 21-day calendar line on top of the visual rule rather than leaving the call to the eye alone. On these two labels, the visual check is the floor, not the ceiling.

Where the mixing math gets typed in

Why no tool lives here: the calendar question sits downstream of the arithmetic, and the arithmetic already has homes.

• Reconstitution calculator: a vial size and a water amount go in, and the concentration plus the volume behind any stated amount come out, the same figures that decide how many draws a mixed vial holds.
• The peptide dose math index: every calculator and explainer in this set, indexed on one page.

More dose math

The page that picks this up directly: the one about what the diluent is, since half the stability question is a question about the water.

• How bac water volume changes your units: the mixing side of the same vial: why the water amount chosen on day one sets every unit reading that follows.

How this page is sourced

Documents first, then papers: seven fetched documents anchor the practical claims, three prescribing information labels plus a compounding chapter's questions and answers, one federal regulation and two European notes for guidance, and ten PubMed-indexed papers carry the stability science. Those are firsthand; the community windows are labeled as reported practice, not verified data.

The community numbers: the fridge, room-temperature, and freezer windows are flagged as reported practice wherever they appear on this page, because we found no published per-compound study behind any of them.

The standard: the full sourcing and citation-verification standard for this site lives on the methodology page. Corrections to any number on this page land there first.

What changed on 28 July 2026: the community table gained a source column so every verified row names its own document at scan speed, and the diluent questions were routed to the bacteriostatic water page rather than half-answered here. No figure was added, removed or altered.

What changed on 29 July 2026: this page used to state that no vendor publishes a post-mixing curve. That was an absence claim covering a whole market, we had no survey behind it, and it is gone. Rerunning the search turned up three published post-mixing studies instead, on sincalide, on a fibrin sealant and on semaglutide in solution, and all three are now cited and described for what they measured. The BPC-157 gap is also no longer ours to assert: a 2026 review that searched three databases reports it.

What those three are, and what they are not: they are the post-mixing studies our search surfaced, not a systematic review of the literature. We have not run a search string that would define this set, and we do not claim it is complete. Post-reconstitution stability is published product by product under each manufacturer's own conditions, so no single query collects it, and any page that prints a count of these papers is asserting more than a search can deliver. They are three worked examples of what a measured window looks like when someone publishes one, and nothing more than that.

What changed on 2 August 2026: the water's own clock moved onto this page instead of being routed away from it. The opened-container question, the unopened-container question and the 28-day figure are now answered here from the approved label, from the compounding chapter's questions and answers, and from the expiration-dating regulation, all three of which are new entries in the list below. No figure already on the page was added to, removed or altered.

What else changed on 2 August 2026: the in-use shelf life got its own section, so the page now names the clock it has been describing all along and says who is supposed to set it, from the two European notes for guidance that define the study and print the model label wording. The 24-hour default and the 28-day ceiling in those documents are new figures on this page, both quoted as label wording for approved products rather than as windows for anything sold for research. The shelf-life extension report was added to the unopened-container question for the same reason: it measures what a printed expiration date can hide, which is a different quantity from every other number here.

Last reviewed: 2 August 2026.

1. 1

   Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. doi:10.1098/rsfs.2017.0030. PMID 29147559.

2. 2

   Sandoz Inc. Omnitrope (somatropin) injection, for subcutaneous use, prescribing information. Label current July 2025. DailyMed, U.S. National Library of Medicine. Omnitrope label, setid 58d84ffa-4056-4e36-ad67-7bd4aef444a5.

3. 3

   Saoji K, Trehan H, Narayanan R, Verma L. A study on the contamination of injection bevacizumab on storage of multidose vials. Indian J Ophthalmol. 2018;66(2):252-255. doi:10.4103/ijo.IJO_969_16. PMID 29380769.

4. 4

   Hospira, Inc. Bacteriostatic Water for Injection, USP, prescribing information. Revised August 2019. DailyMed, U.S. National Library of Medicine. Bacteriostatic Water label, setid 87d6e9dc-fe3b-4593-ac9a-d7493d1959c7.

5. 5

   Angkawinitwong U, Sharma G, Khaw PT, Brocchini S, Williams GR. Solid-state protein formulations. Ther Deliv. 2015;6(1):59-82. doi:10.4155/tde.14.98. PMID 25565441.

6. 6

   Bian YZ, Guo C, Chang TM. Temperature stability of Poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] in the form of a solution or in the lyophilized form during storage at -80°C, 4°C, 25°C and 37°C or pasteurization at 70°C. Artif Cells Nanomed Biotechnol. 2016;44(1):41-47. doi:10.3109/21691401.2015.1110871. PMID 26613265.

7. 7

   Eberhard U, Broder M, Witzke G. Stability of Beriplast P fibrin sealant: storage and reconstitution. Int J Pharm. 2006;313(1-2):1-4. doi:10.1016/j.ijpharm.2005.12.001. PMID 16530994.

8. 8

   Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res. 2012;29(1):236-250. doi:10.1007/s11095-011-0538-y. PMID 21805212.

9. 9

   Belanger E, Wolf SM, Zatt SA, Christoff J, Rojeab Y. Chemical Stability of Reconstituted Sincalide in Sterile Water Under 2 Different Storage Conditions. J Nucl Med Technol. 2020;48(2):174-176. doi:10.2967/jnmt.119.230441. PMID 32111658.

10. 10

    Malgave A, Akbar S, Joseph A, Dande A, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery. Eur J Pharm Biopharm. 2025;214:114780. doi:10.1016/j.ejpb.2025.114780. PMID 40490042.

11. 11

    Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625. PMID 42198317.

12. 12

    United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding, Sterile Preparations: frequently asked questions, updated 11 December 2023, questions 188, 193 and 195. USP document.

13. 13

    TM Biowater, Inc. TM BIOWATER, bacteriostatic water injection, 30 mL multiple-dose vial, NDC 87597-003-30, storage and handling. Filed under the marketing category unapproved drug other, and carrying the agency notice that FDA has not found the drug safe and effective and has not approved its labeling. SPL version 4, effective 18 June 2026. DailyMed, U.S. National Library of Medicine. Current label, set id 4af596eb-7f27-dc59-e063-6294a90aa12b.

14. 14

    U.S. Code of Federal Regulations, Title 21, Part 211, Subpart G, Section 211.137, Expiration dating, paragraphs (a), (b) and (c). U.S. Government Publishing Office. 21 CFR 211.137.

15. 15

    Committee for Proprietary Medicinal Products. Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution, CPMP/QWP/159/96 corr. London, 28 January 1998, date for coming into operation July 1998. European Medicines Agency. Guidance PDF, CPMP/QWP/159/96 corr.

16. 16

    Committee for Proprietary Medicinal Products. Note for guidance on in-use stability testing of human medicinal products, CPMP/QWP/2934/99. London, 1 March 2001, date for coming into operation September 2001. European Medicines Agency. Guidance PDF, CPMP/QWP/2934/99.

17. 17

    Lyon RC, Taylor JS, Porter DA, Prasanna HR, Hussain AS. Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci. 2006;95(7):1549-1560. doi:10.1002/jps.20636. PMID 16721796.